

Stefania Scala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2166786/publications.pdf>

Version: 2024-02-01

119
papers

5,603
citations

66343

42
h-index

88630

70
g-index

121
all docs

121
docs citations

121
times ranked

8814
citing authors

#	ARTICLE	IF	CITATIONS
1	In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies. , 2022, 10, e004032.		25
2	Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients. Cancers, 2022, 14, 1849.	3.7	3
3	At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer. Journal of Leukocyte Biology, 2021, 109, 969-989.	3.3	28
4	Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592198922.	3.2	7
5	PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. Journal of Experimental and Clinical Cancer Research, 2021, 40, 22.	8.6	37
6	Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors. Journal of Medicinal Chemistry, 2021, 64, 3449-3461.	6.4	8
7	CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment. Frontiers in Oncology, 2021, 11, 591386.	2.8	49
8	A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. Molecular Therapy, 2021, 29, 2963-2978.	8.2	9
9	Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal. Cancers, 2021, 13, 3284.	3.7	8
10	Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study. Cancers, 2021, 13, 4236.	3.7	8
11	CXCL12 Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1302, 51-70.	1.6	26
12	Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110114.	3.2	21
13	Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Seminars in Cancer Biology, 2020, 60, 351-361.	9.6	122
14	Study of Ras Mutationsâ€™™ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. Cancers, 2020, 12, 1919.	3.7	25
15	New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer. Cancers, 2020, 12, 1952.	3.7	16
16	Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. Cancers, 2020, 12, 3073.	3.7	28
17	CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells. Frontiers in Immunology, 2020, 11, 02168.	4.8	20
18	Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. Cancers, 2020, 12, 2422.	3.7	5

#	ARTICLE	IF	CITATIONS
19	Fighting the Host Reaction to SARS-CoV-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs. <i>Frontiers in Immunology</i> , 2020, 11, 1201.	4.8	15
20	Disulfide Bond Replacement with 1,4- and 1,5-Disubstituted [1,2,3]-Triazole on CXCR4 Chemokine Receptor Type 4 (CXCR4) Peptide Ligands: Small Changes that Make Big Differences. <i>Chemistry - A European Journal</i> , 2020, 26, 10113-10125.	3.3	10
21	Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients. <i>Immunotherapy</i> , 2020, 12, 105-110.	2.0	33
22	Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer. <i>Cell Death and Disease</i> , 2020, 11, 275.	6.3	21
23	New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM. <i>Vaccines</i> , 2020, 8, 164.	4.4	9
24	Prognostic and Predictive Role of CXC Chemokine Receptor 4 in Metastatic Colorectal Cancer Patients. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 755-760.	1.2	12
25	CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells. <i>Cell Death and Disease</i> , 2019, 10, 562.	6.3	9
26	Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 432.	8.6	74
27	Cetuximab, irinotecan and fluorouracil in first-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. <i>BMC Cancer</i> , 2019, 19, 899.	2.6	10
28	Ionizing radiation effects on the tumor microenvironment. <i>Seminars in Oncology</i> , 2019, 46, 254-260.	2.2	50
29	Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. <i>Cancer Management and Research</i> , 2019, Volume 11, 3847-3860.	1.9	78
30	Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4) Ligand Interactions on Living Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2910-2923.	6.4	22
31	Cationic nucleopeptides as novel non-covalent carriers for the delivery of peptide nucleic acid (PNA) and RNA oligomers. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2539-2550.	3.0	10
32	Predictive immune biomarkers: an unattainable chimera?. <i>Cellular and Molecular Immunology</i> , 2018, 15, 740-742.	10.5	5
33	Engineering of thermoresponsive gels as a fake metastatic niche. <i>Carbohydrate Polymers</i> , 2018, 191, 112-118.	10.2	9
34	Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 297.	8.6	11
35	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. <i>Journal of Translational Medicine</i> , 2017, 15, 46.	4.4	85
36	Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9641-9652.	6.4	21

#	ARTICLE	IF	CITATIONS
37	A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors. <i>Scientific Reports</i> , 2017, 7, 2554.	3.3	17
38	Epithelial-to-mesenchymal transition in FHC-silenced cells: the role of CXCR4/CXCL12 axis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 104.	8.6	47
39	Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. <i>Oncotarget</i> , 2017, 8, 77110-77120.	1.8	59
40	Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy. <i>World Journal of Clinical Cases</i> , 2017, 5, 390.	0.8	8
41	Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach. <i>Oncotarget</i> , 2017, 8, 41890-41902.	1.8	47
42	Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. <i>International Journal of Molecular Sciences</i> , 2016, 17, 790.	4.1	32
43	CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. <i>Oncotarget</i> , 2016, 7, 18865-18875.	1.8	26
44	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. <i>Cancer Treatment Reviews</i> , 2016, 48, 61-68.	7.7	102
45	CXCR4, CXCL12, CXCR7, TLR2, TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. <i>OncoImmunology</i> , 2016, 5, e1254313.	4.6	36
46	Tumour biomarkers: homeostasis as a novel prognostic indicator. <i>Open Biology</i> , 2016, 6, 160254.	3.6	21
47	Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. <i>BMC Cancer</i> , 2016, 16, 918.	2.6	60
48	Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8369-8380.	6.4	26
49	Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 55.	8.6	89
50	Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy. <i>Oncology</i> , 2016, 90, 36-42.	1.9	60
51	CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. <i>Nanoscale</i> , 2016, 8, 7562-7571.	5.6	15
52	Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy. <i>Cancer Immunology Research</i> , 2016, 4, 366-374.	3.4	61
53	A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion. <i>Cancer Letters</i> , 2016, 370, 100-107.	7.2	74
54	Prognostic role of the <i>CDKN1B</i> V109G polymorphism in multiple endocrine neoplasia type 1. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 1735-1741.	3.6	23

#	ARTICLE	IF	CITATIONS
55	Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer. <i>Scientific Reports</i> , 2015, 5, 10357.	3.3	87
56	Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. <i>Oncotarget</i> , 2015, 6, 8261-8270.	1.8	54
57	Conformational Ensembles Explored Dynamically from Disordered Peptides Targeting Chemokine Receptor CXCR4. <i>International Journal of Molecular Sciences</i> , 2015, 16, 12159-12173.	4.1	7
58	Molecular Pathways: Targeting the CXCR4/CXCL12 Axis: Untapped Potential in the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2015, 21, 4278-4285.	7.0	221
59	Intrinsically disordered amphiphilic peptides as potential targets in drug delivery vehicles. <i>Molecular BioSystems</i> , 2015, 11, 2925-2932.	2.9	6
60	Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it. <i>International Journal of Surgery</i> , 2015, 21, S89-S94.	2.7	17
61	CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not. <i>Cellular and Molecular Immunology</i> , 2015, 12, 474-482.	10.5	39
62	A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. <i>International Journal of Cancer</i> , 2014, 135, 379-390.	5.1	32
63	Peptides targeting chemokine receptor CXCR4: structural behavior and biological binding studies. <i>Journal of Peptide Science</i> , 2014, 20, 270-278.	1.4	8
64	CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. <i>Cell Death and Disease</i> , 2014, 5, e1310-e1310.	6.3	70
65	Tissue Micro Arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 1814-8.	0.5	0
66	Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. <i>BJU International</i> , 2013, 112, 686-696.	2.5	70
67	Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition. <i>Frontiers in Immunology</i> , 2013, 3, 409.	4.8	0
68	Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration. <i>Cancer Biology and Therapy</i> , 2013, 14, 175-183.	3.4	15
69	Radiation therapy following surgery for localized breast cancer: outcome prediction by classical prognostic factors and approximated genetic subtypes. <i>Journal of Radiation Research</i> , 2013, 54, 292-298.	1.6	9
70	Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases. <i>PLoS ONE</i> , 2013, 8, e74548.	2.5	76
71	Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. <i>Tumori</i> , 2013, 99, 293e-8e.	1.1	3
72	CXCL12-binding receptors expression in non-small cell lung cancer relates to tumoral microvascular density and CXCR4 positive circulating tumoral cells in lung draining venous blood. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 41, 368-375.	1.4	33

#	ARTICLE	IF	CITATIONS
73	High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer. <i>Current Cancer Drug Targets</i> , 2012, 12, 693-702.	1.6	28
74	Inhibition of stromal CXCR4 impairs development of lung metastases. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1713-1720.	4.2	55
75	IRF-8 Controls Melanoma Progression by Regulating the Cross Talk between Cancer and Immune Cells within the Tumor Microenvironment. <i>Neoplasia</i> , 2012, 14, 1223-IN43.	5.3	48
76	Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. <i>Journal of Translational Medicine</i> , 2012, 10, 232.	4.4	34
77	Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. <i>European Journal of Heart Failure</i> , 2012, 14, 130-137.	7.1	77
78	The N-terminal Region of CXCL11 as Structural Template for CXCR3 Molecular Recognition: Synthesis, Conformational Analysis, and Binding Studies. <i>Chemical Biology and Drug Design</i> , 2012, 80, 254-265.	3.2	14
79	A possible predictive marker of progression for hepatocellular carcinoma. <i>Oncology Letters</i> , 2011, 2, 1247-1251.	1.8	21
80	Prostate Cancer Detection in the "Grey Area" of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3. <i>European Urology</i> , 2011, 59, 81-87.	1.9	73
81	CD4+CD45RA+CXCR4+ lymphocytes are inversely associated with progression in stages I-III melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 511-517.	4.2	1
82	Cetuximab-dependent ADCC in cancer: dream or reality?. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1607-1608.	4.2	7
83	Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. <i>Biochemical Pharmacology</i> , 2010, 79, 817-824.	4.4	312
84	HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. <i>Clinical Immunology</i> , 2010, 134, 237-250.	3.2	131
85	Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. <i>Cancer Biology and Therapy</i> , 2010, 9, 423-429.	3.4	30
86	Differential role of CD133 and CXCR4 in renal cell carcinoma. <i>Cell Cycle</i> , 2010, 9, 4492-4500.	2.6	77
87	Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer. <i>Current Cancer Drug Targets</i> , 2010, 10, 772-781.	1.6	73
88	Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. <i>Journal of Translational Medicine</i> , 2010, 8, 109.	4.4	27
89	Serum cytokine levels in patients with hepatocellular carcinoma. <i>European Cytokine Network</i> , 2010, 21, 99-104.	2.0	45
90	CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression. <i>Frontiers in Bioscience - Elite</i> , 2010, E2, 13-21.	1.8	27

#	ARTICLE	IF	CITATIONS
91	Interaction between HMGA1 and Retinoblastoma Protein Is Required for Adipocyte Differentiation. <i>Journal of Biological Chemistry</i> , 2009, 284, 25993-26004.	3.4	16
92	A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration. <i>Cell Cycle</i> , 2009, 8, 1228-1237.	2.6	11
93	Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus <i>doi:10.1158/1078-0432.CCR-08-1467</i>. <i>Clinical Cancer Research</i> , 2008, 14, 6505-6514.	7.0	64
94	CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1589-1595.	4.2	36
95	Soluble interleukin-2 receptor in stage I-III melanoma. <i>Cytokine</i> , 2006, 33, 150-155.	3.2	24
96	Adjuvant treatment of malignant melanoma: Where are we?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 45-52.	4.4	10
97	Overexpression of Both CXC Chemokine Receptor 4 and Vascular Endothelial Growth Factor Proteins Predicts Early Distant Relapse in Stage II-III Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2006, 12, 2795-2803.	7.0	158
98	Human Melanoma Metastases Express Functional CXCR4. <i>Clinical Cancer Research</i> , 2006, 12, 2427-2433.	7.0	114
99	Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 44-50.	4.2	12
100	Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 781-791.	4.2	78
101	Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma. <i>Clinical Cancer Research</i> , 2005, 11, 1835-1841.	7.0	260
102	Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. <i>Journal of Clinical Oncology</i> , 2005, 23, 7660-7668.	1.6	218
103	Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells. <i>Biochemical Pharmacology</i> , 2005, 70, 1277-1287.	4.4	26
104	Temozolomide and cisplatin in advanced malignant melanoma. <i>Anticancer Research</i> , 2005, 25, 1441-7.	1.1	11
105	Prognostic value of serum VEGF in melanoma patients: a pilot study. <i>Anticancer Research</i> , 2004, 24, 4255-8.	1.1	28
106	ONYX-015, an E1B Gene-Defective Adenovirus, Induces Cell Death in Human Anaplastic Thyroid Carcinoma Cell Lines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2525-2531.	3.6	50
107	Cellular and Biophysical Evidence for Interactions between Adenosine Triphosphate and P-Glycoprotein Substrates: Functional Implications for Adenosine Triphosphate/Drug Cotransport in P-Glycoprotein Overexpressing Tumor Cells and in P-Glycoprotein Low-Level Expressing Erythrocytes. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 181-200.	1.4	18
108	HMGI-C gene expression is not required for in vivo thyroid cell transformation. <i>Carcinogenesis</i> , 2001, 22, 251-256.	2.8	11

#	ARTICLE	IF	CITATIONS
109	Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation. <i>Molecular and Cellular Biology</i> , 2001, 21, 2485-2495.	2.3	86
110	Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 4256-4261.	7.1	146
111	Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. <i>Oncogene</i> , 1998, 17, 413-418.	5.9	113
112	Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. <i>Oncogene</i> , 1998, 17, 377-385.	5.9	51
113	P-Glycoprotein Substrates and Antagonists Cluster into Two Distinct Groups. <i>Molecular Pharmacology</i> , 1997, 51, 1024-1033.	2.3	228
114	Cystic Fibrosis Transmembrane Conductance Regulator and Adenosine Triphosphate. <i>Science</i> , 1997, 275, 1324-1326.	12.6	99
115	Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 245-250.	2.3	28
116	Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. <i>Journal of Cellular Biochemistry</i> , 1997, 65, 513-526.	2.6	87
117	Coexpression of TGF β , Epidermal Growth Factor Receptor, and P-Glycoprotein in Normal and Benign Diseased Breast Tissues. <i>Diagnostic Molecular Pathology</i> , 1995, 4, 136-142.	2.1	16
118	Cell surface expression of major histocompatibility class I antigens is modulated by P-glycoprotein transporter. <i>Human Immunology</i> , 1995, 42, 245-253.	2.4	5
119	Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells. <i>Journal of Clinical Investigation</i> , 1995, 96, 1026-1034.	8.2	38